Pituitary, ovarian and endometrial effects of 300 μg norethisterone and 30 μg levonorgestrel administered on cycle days 7 to 10

Autor: A.-R. Aedo, B. Diczfalusy, E. Johannisson, O. Dada, B-M. Landgren

Publikováno v: Contraception. 41:569-581

The ovarian, endometrial and pituitary effects of 300 μg norethisterone (NET) and 30 fig levonorgestrel (L-NOG) administered orally on cycle days 7–10 were investigated in two groups of 10 women each, by daily analysis of plasma estradiol (E 2 ),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88f5f035d7122ce8e0b0c24780e13f77
https://doi.org/10.1016/s0010-7824(09)91002-2

Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.

Autor: Taya, Yuki^1,2 (AUTHOR), Mizunaga, Mari² (AUTHOR), Nakao, Shunsuke² (AUTHOR), Jutanom, Mirinthorn¹ (AUTHOR), Shimizu, Naoki¹ (AUTHOR), Nomura, Yukihiro² (AUTHOR), Nakagawa, Kiyotaka¹ (AUTHOR) kiyotaka.nakagawa.c1@tohoku.ac.jp

Publikováno v: Molecules. Feb2023, Vol. 28 Issue 4, p1576. 15p.

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

Autor: Thurman, Andrea R.¹ (AUTHOR) thurmaar@evms.edu, Brache, Vivian² (AUTHOR), Cochon, Leila² (AUTHOR), Ouattara, Louise A.¹ (AUTHOR), Chandra, Neelima¹ (AUTHOR), Jacot, Terry¹ (AUTHOR), Yousefieh, Nazita¹ (AUTHOR), Clark, Meredith R.¹ (AUTHOR), Peet, Melissa¹ (AUTHOR), Hanif, Homaira¹ (AUTHOR), Schwartz, Jill L.¹ (AUTHOR), Ju, Susan¹ (AUTHOR), Marzinke, Mark A.³ (AUTHOR), Erikson, David W.⁴ (AUTHOR), Parikh, Urvi⁵ (AUTHOR), Herold, Betsy C.⁶ (AUTHOR), Fichorova, Raina N.⁷ (AUTHOR), Tolley, Elizabeth⁸ (AUTHOR), Doncel, Gustavo F.¹ (AUTHOR)

Publikováno v: PLoS ONE. 10/10/2022, Vol. 17 Issue 10, p1-30. 30p.

Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.

Autor: Aklillu, Eleni¹ (AUTHOR) eleni.aklillu@ki.se, Zumla, Alimuddin^2,3 (AUTHOR), Habtewold, Abiy⁴ (AUTHOR), Amogne, Wondwossen⁵ (AUTHOR), Makonnen, Eyasu⁶ (AUTHOR), Yimer, Getnet⁶ (AUTHOR), Burhenne, Jürgen⁷ (AUTHOR), Diczfalusy, Ulf⁸ (AUTHOR)

Publikováno v: British Journal of Pharmacology. Aug2021, Vol. 178 Issue 16, p3294-3308. 15p. 1 Diagram, 3 Charts, 4 Graphs.

Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.

Autor: Sun, Wan¹ (AUTHOR), Lirio, Richard A.¹ (AUTHOR) Richard.Lirio@takeda.com, Schneider, Jennifer² (AUTHOR), Aubrecht, Jiri¹ (AUTHOR), Kadali, Harisha¹ (AUTHOR), Baratta, Mike¹ (AUTHOR), Gulati, Parul¹ (AUTHOR), Suri, Ajit¹ (AUTHOR), Lin, Tiffany² (AUTHOR), Vasudevan, Raghavan¹ (AUTHOR), Rosario, Maria¹ (AUTHOR)

Publikováno v: Clinical Pharmacology in Drug Development. Jul2021, Vol. 10 Issue 7, p734-747. 14p.